Industry | 制造业 | ||||||||||||||||||||||||
Company Introduction | 湖北广济药业股份有限公司是以生产、销售医药原料药及制剂、兽药原料药、饲料添加剂和精细化工为主的国家重点高新技术上市企业.公司主要生产经营医药原料药、医药制剂和饲料添加剂等,主导产品为核黄素和替硝唑.公司是湖北省首批现代企业制度试点单位,曾荣获全国"五一"劳动奖状,是中国最大的核黄素生产基地,2010年,公司被评为"国家火炬计划重点高新技术企业","湖北省医药行业生产十强企业"。 | ||||||||||||||||||||||||
Main Business | 生产经营医药原料药、医药制剂、饲料添加剂,出口本企业自产的各类药。 | ||||||||||||||||||||||||
Legal Representative | 胡立刚 | ||||||||||||||||||||||||
Top Executives |
|
||||||||||||||||||||||||
Top 5 Shareholder |
|
||||||||||||||||||||||||
Company Secretary | 郑彬 | ||||||||||||||||||||||||
Solicitors | 北京市嘉源律师事务所 | ||||||||||||||||||||||||
Auditors | 大信会计师事务所(特殊普通合伙) | ||||||||||||||||||||||||
Tel No | 17371575571 | ||||||||||||||||||||||||
Fax No | 0713-6211112 | ||||||||||||||||||||||||
Website | www.guangjipharm.com | ||||||||||||||||||||||||
stock@guangjipharm.com;gjyystock@163.com | |||||||||||||||||||||||||
Company Address |
|
||||||||||||||||||||||||
Listing Date | 12/11/1999 | ||||||||||||||||||||||||
Shares Capital |
|
||||||||||||||||||||||||
EPS(RMB)* | ¥ -0.396 | ||||||||||||||||||||||||
DPS(RMB)* | -- | ||||||||||||||||||||||||
NBV Per Share(RMB)* | ¥ 3.852 | ||||||||||||||||||||||||
Market Capitalization(RMB) | 1.823B |
![]() |
Only Chinese content is avaliable |
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
* | Unadjusted Data |
Information provided by: etnet | ||
Terms and Conditions |
Risk Disclosure: |
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
Disclaimer: |
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Chiyu Banking Corporation Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |